MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New therapy to prevent heart failure

Back to heart watch blog Blogs list Cancer blog  


Subscribe To Heart Watch Blog RSS Feed  RSS content feed What is RSS feed?

New therapy to prevent heart failure




A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization treatment device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only).



New therapy to prevent heart failure

MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) is a clinical trial that enrolled more than 1,800 patients in the United States, Canada and Europe and followed the patients for up to 4 years. The results of the trial were released recently by the University of Rochester Medical Center and Boston Scientific, the study's sponsor. The MADIT-CRT Executive Committee stopped the trial on June 22, 2009, when the trial achieved its primary end point significant reduction in heart failure or death with CRT-D versus ICD-only. Heart specialist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, led the MADIT-CRT trial.

A previous study (MADIT-II) by Moss and associates in 2002 showed the ICD was effective in reducing mortality. The current MADIT-CRT study sought to determine if CRT-D could reduce the risk of mortality and heart failure, which affects 5.7 million Americans, and the results are very positive.

Patients with heart disease have a risk of arrhythmias and heart failure. The new generation of cardiac resynchronization treatment defibrillators (CRT-Ds) was designed to stop dangerous, life-threatening heart rhythms and improve the heart's contraction, thereby enabling the device to improve survival and prevent heart failure.

CRT-D's are approved for use in patients with severe heart failure (New York Heart Association class III/IV), where they have been shown to reduce heart failure symptoms. The findings from the current study indicate that CRT-D treatment improves cardiac function and prevents the development of heart failure in patients who have not previously experienced heart failure.

"Now we can prevent sudden cardiac death and inhibit the development of heart failure, thus improving survival and outcome in patients with heart disease," Moss said. "There is a very large population of patients with heart disease who will benefit from this combined treatment".


Posted by: Daniel    Source




Did you know?
A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization treatment device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only).

Medicineworld.org: New therapy to prevent heart failure

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.